| James D Campbell, DO | |
|
300 Rockefeller Dr, Muskogee, OK 74401-5075 | |
| (918) 781-9466 | |
| Not Available |
| Full Name | James D Campbell |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 31 Years |
| Location | 300 Rockefeller Dr, Muskogee, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932185212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 3180 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital | Stilwell, OK | Hospital |
| Sequoyah County-city Of Sallisaw Hospital Authorit | Sallisaw, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Adair County Health Center Inc | 9638065907 | 17 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
| Entity Name | Adair County Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972780765 PECOS PAC ID: 9638065907 Enrollment ID: O20040224000664 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
| Entity Name | Green Country Emergency Physicians Group Of Tulsa, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972698553 PECOS PAC ID: 0345247052 Enrollment ID: O20061021000024 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
| Entity Name | Emergency Physicians Of Mid-america Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063825297 PECOS PAC ID: 2062638661 Enrollment ID: O20140716001692 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
| Entity Name | Oklahoma Emergency Partners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245945039 PECOS PAC ID: 1951776020 Enrollment ID: O20230404001494 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James D Campbell, DO Lockbox # 17, 2424 East 21st Street, Suite 100, Tulsa, OK 74114-1711 Ph: (866) 321-8433 | James D Campbell, DO 300 Rockefeller Dr, Muskogee, OK 74401-5075 Ph: (918) 781-9466 |
News Archive
Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
The decision was applauded by many researchers and drew speculation that it could likely boost patient care. Meanwhile, the stock of Myriad Genetics tumbled after the court's finding invalidated the company's hold on testing for two breast cancer genes.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 3 days ago
Eric W Mix, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 Rockefeller Dr, Muskogee, OK 74401 Phone: 918-781-9466 | |
Dr. Vernon Lee Jenkins, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1011 Honor Heights Dr, Muskogee, OK 74401 Phone: 918-680-3662 Fax: 918-680-3664 | |
Dr. Jeffrey L. Anderson, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1011 Honor Heights Dr, Muskogee, OK 74401 Phone: 918-683-3261 | |
Berry E Winn, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Rockefeller Dr, Muskogee, OK 74401 Phone: 918-781-9466 | |
Kimberly R Gage, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Rockefeller Dr, Muskogee, OK 74401 Phone: 918-781-9466 | |
Joseph A Braden, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Rockefeller Dr, Muskogee, OK 74401 Phone: 918-781-9466 | |
Margaret B Bernhard, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 Rockefeller Dr, Muskogee, OK 74401 Phone: 918-781-9466 |